Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study

Exclusion Criteria

• •Patients who abuse alcohol according to the AUDIT-c questionnaire;
• •Patients taking COC for more than 4 weeks before signing the informed consent;
• •Patients with contraindications to COC;
• •Patients diagnosed with diabetes mellitus;
• •Pregnancy and lactation;
• •Simultaneous use of levodopa, altretamine, cisplatin, statins;
• •Patients with coinfection with HIV, HBV, HCV;
• •Decompensated liver cirrhosis CPT≥7 points;
• •GFR ≤ 15 ml/min/1.73 m2;
• •Drug-induced liver damage;
• •Taking narcotic and psychotropic drugs;
• •Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than \>5 times;
• •patients with pronounced biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 ULN;
• •Participation in an interventional clinical trial.